Tovanor Breezhaler regulatory update

The Pharmaceutical Affairs and Food Sanitation Council of Japan's Ministry of Health, Labor and Welfare (MHLW) recommended approval of a marketing application from Novartis for NVA237 to treat chronic obstructive pulmonary disease (COPD). Novartis, which submitted the application last November, has global rights to NVA237 from Sosei and Vectura under a 2005 deal (see BioCentury, April 18, 2005). ...